This standard has been approved by the Australian Health Workforce Ministerial Council on 31 March 2010 pursuant to the Health Practitioner Regulation National Law (2009) (the National Law) with approval taking effect from 1 July 2010.
The Nursing and Midwifery Board of Australia has established this standard in accordance with sections 38(2) and 94 of the National Law.
This standard sets out the qualifications and other requirements that must be met in order for a registered nurse or applicant for registration as a nurse to be granted an endorsement under section 94 of the National Law as qualified to obtain, supply, and administer scheduled medicines.
Endorsed as qualified to obtain, supply and administer schedule 2,3,4 & 8 medicines for nursing practice in a rural and isolated practice area.
This endorsement applies to a class of registered nurses and not to all registered nurses.
An endorsement under section 94 indicates that the registered nurse is qualified to obtain, supply and administer limited schedule 2, 3, 4 or 8 medicines appropriate to the registered nurse’s scope of practice within the meaning of the current poisons standard under the Therapeutic Goods Act 1989 (Cwlth), s. 52D, to the extent necessary to practise nursing in a particular area and described and listed under the relevant drug therapy protocol, Chief Health Officer standing order or health services permit that must be compliant with relevant State and Territory legislation.
To be eligible for endorsement for scheduled medicines, registered nurses must have completed an approved program of study determined by the Board.
A list of approved programs of study is available on the National Board website.
Endorsed registered nurses are expected to comply with any detailed guidelines on obtaining, supplying and administering scheduled medicines issued from time to time by the Nursing and Midwifery Board of Australia and published in accordance with section 39 of the National Law on the Board’s website.
This endorsement will commence on 1 July 2010. The Board will review this endorsement within 12 months after its commencement.